Lynch Syndrome Clinical Trial
Official title:
Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland
Breast, colorectal, ovarian, and endometrial cancers constitute approximately 30% of newly diagnosed cancer cases in Switzerland and affect more than 12,000 individuals annually. Several hundred of these patients are likely to carry known genetic mutations associated with HBOC or LS. Genetic testing for hereditary susceptibility to cancer can prevent many cancer deaths through early identification and engagement in high-risk management care that involves intensive surveillance, chemoprevention and/or prophylactic surgery. However, current rates of genetic testing indicate that many Swiss mutation carriers and their family members do not use cancer genetic services (counseling and/or testing), either due to lack of coordination of care or due to lack of communication about the mutation among family members. Cascade screening identifies and tests family members of a known mutation carrier. It determines whether asymptomatic family members are carriers of the identified mutation and proposes management options to reduce harmful outcomes. Robust evidence of basic science and descriptive population-based studies in Switzerland support the necessity of cascade screening for HBOC and LS. However, translation of this knowledge into public health interventions is lacking. Specific Aims of the CASCADE study are: 1. Survey Index Patients diagnosed with HBOC or LS from clinic-based genetic testing records and determine their cancer status and surveillance practices; needs for coordination of medical care; psychosocial needs; patient-provider and patient-family communication needs; quality of life; willingness to serve as advocates for cancer genetic services for blood relatives. 2. Survey first- and second-degree relatives, and first cousins identified from pedigrees and/or family history records of HBOC and LS Index Patients and determine their cancer and mutation status; cancer surveillance practices; needs for coordination of medical care; barriers and facilitators to using cancer genetic services; psychosocial needs; patient-provider and patient-family communication needs; quality of life; willingness to participate in a study designed to increase use of cancer genetic services. 3. Explore the influence of patient-provider communication about genetic cancer risk on patient-family communication and the acceptability of a family-based communication, coping, and decision support intervention with focus group(s) of mutation carriers and blood relatives.
Please see study protocol provided in the references ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00217737 -
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
|
Phase 3 | |
Completed |
NCT00905710 -
Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome
|
N/A | |
Active, not recruiting |
NCT02194387 -
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
|
N/A | |
Recruiting |
NCT04909671 -
Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome.
|
N/A | |
Recruiting |
NCT04379999 -
Atorvastatin ± Aspirin in Lynch Syndrome Syndrome
|
Early Phase 1 | |
Recruiting |
NCT05692596 -
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
|
||
Completed |
NCT01845753 -
Molecular Screening for Lynch Syndrome in Denmark
|
||
Completed |
NCT01216930 -
Molecular Screening for Lynch Syndrome in Southern Denmark
|
N/A | |
Not yet recruiting |
NCT05963191 -
CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome
|
N/A | |
Active, not recruiting |
NCT02912559 -
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
|
Phase 3 | |
Recruiting |
NCT04978350 -
Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study
|
N/A | |
Active, not recruiting |
NCT03832985 -
Pediatric Reporting of Adult-Onset Genomic Results
|
Early Phase 1 | |
Withdrawn |
NCT04778566 -
Evaluating the Cologuard Test for Use in Lynch Syndrome
|
||
Completed |
NCT02570516 -
NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome
|
N/A | |
Completed |
NCT01823471 -
I-Scan For Colon Polyp Detection In HNPCC
|
N/A | |
Recruiting |
NCT02813824 -
Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome
|
Phase 3 | |
Recruiting |
NCT05078866 -
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT03744962 -
MSI in Circulatory DNA of Endometrial Cancer
|
||
Recruiting |
NCT04711434 -
PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients
|
Phase 3 | |
Completed |
NCT04131062 -
Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants
|
N/A |